Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells
Overview
Authors
Affiliations
Immune exhaustion is an important feature of chronic infections, such as HIV, and a barrier to effective immunity against cancer. This dysfunction is in part controlled by inhibitory immune checkpoints. Blockade of the PD-1 or IL-10 pathways can reinvigorate HIV-specific CD4 T cell function in vitro, as measured by cytokine secretion and proliferative responses upon Ag stimulation. However, whether this restoration of HIV-specific CD4 T cells can improve help to other cell subsets impaired in HIV infection remains to be determined. In this study, we examine a cohort of chronically infected subjects prior to initiation of antiretroviral therapy (ART) and individuals with suppressed viral load on ART. We show that IFN-γ induction in NK cells upon PBMC stimulation by HIV Ag varies inversely with viremia and depends on HIV-specific CD4 T cell help. We demonstrate in both untreated and ART-suppressed individuals that dual PD-1 and IL-10 blockade enhances cytokine secretion of NK cells via restored HIV-specific CD4 T cell function, that soluble factors contribute to these immunotherapeutic effects, and that they depend on IL-2 and IL-12 signaling. Importantly, we show that inhibition of the PD-1 and IL-10 pathways also increases NK degranulation and killing of target cells. This study demonstrates a previously underappreciated relationship between CD4 T cell impairment and NK cell exhaustion in HIV infection, provides a proof of principle that reversal of adaptive immunity exhaustion can improve the innate immune response, and suggests that immune checkpoint modulation that improves CD4/NK cell cooperation can be used as adjuvant therapy in HIV infection.
From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.
Laeremans T, Janssens A, Aerts J Immunotherapy. 2025; 17(2):133-145.
PMID: 39905963 PMC: 11901454. DOI: 10.1080/1750743X.2025.2460965.
Immune checkpoint inhibitors in infectious disease.
King H, Lewin S Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.
de Taeye S, Schriek A, Umotoy J, Grobben M, Burger J, Sanders R Commun Biol. 2024; 7(1):964.
PMID: 39122901 PMC: 11316088. DOI: 10.1038/s42003-024-06659-8.
HIV Expression in Infected T Cell Clones.
Rausch J, Parvez S, Pathak S, Capoferri A, Kearney M Viruses. 2024; 16(1).
PMID: 38257808 PMC: 10820123. DOI: 10.3390/v16010108.
Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.
Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera B, Jain P Pathogens. 2024; 13(1).
PMID: 38251321 PMC: 10821063. DOI: 10.3390/pathogens13010014.